Obinutuzumab for Rituximab-Intolerant Minimal Change Disease: A Case Report and Review of Recent Literature. [PDF]
Shan HY.
europepmc +1 more source
Humanized Antibodies Targeting Ectodomains of IL-6R and GP130 Suppress IL-6/STAT3 Signalling and Tumour Growth in Breast Cancer Models. [PDF]
Pereira SD +10 more
europepmc +1 more source
Allergen‐specific IgG4 mAbs were shown to block facilitated IgE binding to B cells and redirect allergens towards myeloid APC, leading to increased IL‐10 production in vitro. In combination with oral AIT, the mAbs inhibited mast cell activation and sustained allergen‐specific IgG4 levels in an in vivo model of peanut allergy. ABSTRACT Background Peanut
Pascal Gasser +12 more
wiley +1 more source
A dual-action humanized DKK-1 antibody that activates the Wnt/β-catenin signaling pathway and inhibits the RANKL signaling pathway for osteoporosis therapy. [PDF]
Hou S +8 more
europepmc +1 more source
ABSTRACT Loncastuximab tesirine (LT) is an antibody‐drug conjugate (ADC), a novel class of therapeutics that combines a target‐specific monoclonal antibody with a cytotoxic agent via a chemical linker. LT has been approved in the United States as therapy for relapsed or refractory diffuse large B‐cell lymphoma (DLBCL).
Daniella Jaguan +2 more
wiley +1 more source
Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review. [PDF]
Allinovi M +8 more
europepmc +1 more source
Evolving role of Anti-CD20 monoclonal antibodies in rheumatoid arthritis: efficacy, safety, economic perspectives, and future directions-a narrative review. [PDF]
Cao Y +6 more
europepmc +1 more source
Early tocilizumab and outcomes in acute necrotizing encephalopathy
Early tocilizumab and outcome in acute necrotising encephalopathy. Aim To evaluate the timing and safety of tocilizumab in acute necrotizing encephalopathy (ANE). Method This was a multicentre retrospective study evaluating outcomes (modified Rankin Scale [mRS]) in children with ANE treated with tocilizumab. A logistic regression model determined a cut‐
Velda X Han +14 more
wiley +1 more source
Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non-Japanese Individuals. [PDF]
Gupta P, Sharma A, Meibohm B.
europepmc +1 more source
ABSTRACT Background T‐cell prolymphocytic leukemia (T‐PLL) is a rare, aggressive mature T‐cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population‐level outcomes remain poorly defined.
Mirian Brink +17 more
wiley +1 more source

